| Literature DB >> 2899198 |
P E Stevens1, B Riley, S P Davies, P E Gower, E A Brown, W Kox.
Abstract
Continuous arteriovenous haemodialysis (CAVHD) is a new treatment for critically ill patients with renal failure that combines convective and diffusive solute removal. The clearance of urea (14.8-22.1 ml/min) is sufficient to achieve a steady-state urea concentration of 22 mmol/l, even in patients with a high catabolic rate and cardiovascular instability. The technique is simple and does not involve the use of blood pumps or specialised staff. Initial experience in 36 critically ill patients with renal failure indicates that it is safe and reliable, with less associated morbidity than other techniques.Entities:
Mesh:
Substances:
Year: 1988 PMID: 2899198 DOI: 10.1016/s0140-6736(88)90695-2
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321